The role of cetuximab in induction chemotherapy: Comparison of APF-C  (nab-paclitaxel, cisplatin, 5-FU + cetuximab) with APF, both followed by chemoradiation therapy (CRT), in patients with locally advanced head and neck squamous cell carcinoma  (HNSCC).

Authors

Douglas Adkins

Washington University School of Medicine, St. Louis, MO

Douglas Adkins , Jessica C. Ley , Tanya Marya Wildes , Loren S. Michel , Jason Rich , Randal Paniello , Ravi Uppaluri , Wade L. Thorstad , Hiram Alberto Gay , Kathryn Trinkaus , Toni Rachocki , Brian Nussenbaum

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

First Author: Jessica C. Ley

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

First Author: Yoojoo Lim

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus  docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

First Author: D. Adkins

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Concurrent chemoradiotherapy with or without induction chemotherapy for locally advanced head and neck cancer.

First Author: J. J. Caudell